In a reality where many marketed antiviral drugs lose effect because of virus mutation, accelerated by the increased spread and incidence of viruses, there is a significant unmet need for new drugs with improved resistance properties. Vironova meets this need by developing antiviral com-pounds that are less prone to induce virus mutation.

Vironova is developing antiviral drugs against Herpes and Influenza, targeting structural components of the viruses. By utilizing our own virus analysis technology platform, the effects of the new antiviral drugs can be visualized and analyzed.

Experts and experienced organic chemists optimize lead compounds in Vironova’s new fully functional organic chemistry laboratory which has been operational since mid 2011.

Vironova AB

Gävlegatan 22

113 30 Stockholm, Sweden

Tel: +46-(0)8-702 67 90

Fax: +46-(0)8-702 67 91

info@vironova.com

Org.nummer:556678-1463

www.vironova.com

VIRONOVA’S ANTI-HERPES COMPOUNDVironova is developing a topical formulation containing the compound B-220 for the treatment of Herpes labialis, which is an infection caused by herpes simplex virus (HSV).

Herpes - a lifelong disease

Herpes simplex virus 1 (HSV-1) causes a chronic, lifelong infection in >60% of adults and there are currently no therapies approved for the cure of herpes simplex infections. Currently, acyclovir is the only standard treatment option available and the medication can relieve symptoms and shorten an outbreak, but time to healing is not dramatically accelerated. Besides, treatment with acyclovir does not eliminate the infection, instead the virus remain dormant and can be reactivated.

Antiviral effect of B-220

Vironova’s B-220 lead compound in the approved U.S. patent for topical administration against Herpes was first discovered over 4 decades ago. B-220 and analogues of the compound has demonstrated a broad-spectrum potent anti-viral activity against several viruses tested from the herpes- virus group i.e. Herpes simplex virus type 1 (HSV-1), Cytomegalovirus (CMV) and Varicella zoster virus (VZV). B-220 appears to inhibit viral replication at different stages of the virus cycle compared to commercially available standard anti-herpes treatments containing acyclovir (Harmenberg J et al. Antimicrob Agents Chemother. 1988 Nov;32(11):1720-4.).

B-220 (2,3-dimethyl-6-(N,N-dimethylaminoethyl)-6H-indolo-(2,3-b)

quinoxaline (B-220) is the active substance in Vironova’s topical

formulation for treating Herpes Labialis.

Ongoing studies

We are conducting preclinical studies with topical B-220 with the goal of submitting an IND to the FDA. In vitro studies to examine the efficiency of topical B-220, dose response relationship in animal studies, evaluation of tole-rability and toxicity and pharmacokinetic profile of B-220 will be performed.

Intellectual property

The patent for the pharmaceutical formulation for topical administration against herpes virus comprising of the B-220 compound has so far been granted in Australia and other patent applications worldwide are pending. In U.S. granted claims protecting the method of treating a herpes virus infection with a B-220 pharmaceutical formulation has been approved.

Market

The market size for HSV treatments is at least $2 billion annually and an effective treatment could lead to a significant increase in market size.

IN THE UNITED STATES, THERE ARE ESTIMATED

TO BE APPROXIMATELY 500,000 PRIMARY

HSV-1 INFECTIONS EVERY YEAR.

VIRONOVA MEDICAL - HERPES

Different stages of the herpes virus cycle in an infected cell. Virus particles passing through the nucleo-membrane are encapsulated by a

membrane. The image is from the I-Care project, acquired with a transmission electron microscope. Image property of Vironova.